Human immunodeficiency virus type-1 associated lymphoma: Tunisian experience
Abstract number: r2182
Ammari L., Kilani B., Tiouiri ben Aissa H., Kanoun F., Abdelmalek R., Zouiten F., Goubontini A., Ben Chaabane T.
Tunisia is one of African countries where seroprevalence of human immunodeficiency virus (HIV)infection is low. However, lymphoma is considered as the second AIDS-definig illness after Kaposi's sarcoma in our experience.
We report clinical, epidemiological, and histopathological findings in patients with HIVassociated lymphoma.
We retrospectively reviewed all patients aged above 15 years and hospitalized for haematologic disorders from January 1985 and December 2004 in the department of infectious diseases of Rabta Hospital. Patients with a diagnosis of agressive lymphoma were included. The stage of lymphoma was based on Ann Arbor system.
10 patients were reported with HIV-associated lymphoma; 60% were heterosexual and 40% intravenous drug users. The mean age was 34 years (2145 years) and sex ratio was 4.The mean interval between the diagnosis of HIV infection and lymphoma was 2.4 years. The lymphoma was the first AIDS-defining illness in 3 cases. CD4+ lymphocyte count below 200 cell/mm3 are observed in 7 cases, and a mean plasma HIV viral load was 619750 copies/ml. 2 patients were under highly active antiretroviral therapy (HAART) before the diagnosis of lymphoma. All patients had B systemic symptoms (fever, night sweats, fatigue, or loss of body weight). 5 patients had HIV-associated non Hodgkin lymphoma (HIV-NHL): a diffuse large-cell lymphomas (3 cases), a Burkitt's lymphoma (1case) and immunoblastic lymphoma (1case). One patient had a probably primary cerebral lymphoma. 3 patients with HIV-HL were at stage III or IV. Extranodal involvement was observed in 6 cases. 6 patients were treated with chemotherapy and/or radiotherapy. From all patients, only one is still alive15 months after diagnosis.
In our experience, lymphoma remains the most lethal complication of AIDS, associated with a very poor prognosis. Survival may be improved by early diagnosis and restauring immune status with HAART.
|Session name:||XXIst ISTH Congress|
|Back to top|